FibroGen, Inc (NASDAQ:FGEN) Given Consensus Recommendation of “Buy” by Analysts
Shares of FibroGen, Inc (NASDAQ:FGEN) have earned a consensus recommendation of “Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $66.60.
Several equities research analysts have recently weighed in on FGEN shares. Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research report on Monday, June 26th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $48.00 price target on shares of FibroGen in a research report on Monday, June 26th.
FibroGen (FGEN) opened at 44.05 on Tuesday. FibroGen has a 12-month low of $15.60 and a 12-month high of $51.70. The stock’s 50 day moving average is $35.25 and its 200 day moving average is $28.50. The stock’s market capitalization is $3.14 billion.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. The company had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities analysts predict that FibroGen will post ($1.82) earnings per share for the current fiscal year.
In related news, insider K Peony Yu sold 3,721 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $28.95, for a total transaction of $107,722.95. Following the completion of the sale, the insider now owns 221,507 shares of the company’s stock, valued at $6,412,627.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $28.50, for a total transaction of $57,000.00. Following the sale, the director now directly owns 34,000 shares of the company’s stock, valued at approximately $969,000. The disclosure for this sale can be found here. Insiders sold a total of 477,938 shares of company stock valued at $17,570,645 in the last ninety days. Corporate insiders own 14.90% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. purchased a new stake in FibroGen during the first quarter worth approximately $111,000. Quantbot Technologies LP purchased a new stake in FibroGen during the second quarter worth approximately $128,000. SG Americas Securities LLC boosted its stake in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Airain ltd purchased a new stake in FibroGen during the first quarter worth approximately $236,000. Finally, Amalgamated Bank purchased a new stake in FibroGen during the second quarter worth approximately $237,000. 43.03% of the stock is owned by institutional investors.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.